It is widely accepted that basement membrane (BM) components are synthesized by epithelial cells and that production of BM-degrading proteases by cancer cells is necessaty for invasive growth. In this study we used nucleic acid in situ hybridization (ISH) to investigate the presence of "As for 72 KD and 92 KD Type IV collagenase, a1 (IV) chain of Type IV collagen, and laminin B1 chain in 20 breast carcinomas of various histological types. The mRNA signals for 72 KD Type IV collagenase, Type IV collagen, and laminin were much more abundant in stromal fibroblasts and endothelial cells than in carcinoma cells. The signal for 92 KD Type IV mllagenase mRNA was strong in carcinoma cells and Cytochem 42:945-951, 19%) KEY WORDS: Breast cancer; Type IV collagenase; Type IV collagen; Laminin; In situ hybridization.
Introduction
Breast carcinoma is one of the most common cancers in women (1). It comprises a heterogeneous group of tumors with variable prognosis and aggressiveness, which is related to the capacity of malignant cells to invade neighboring tissues and to metastasize to distant sites. Basement membranes (BMs) beneath the epithelial linings and around vascular structures form the first barriers through which the invading and metastasizing cells must penetrate.
Enzymes involved in extracellular matrix degradation are a group of zinc metalloproteinases (MMPs) that share similar characteristics. Among the MMP family, interstitial collagenase (MMP-1) degrades interstitial collagen molecules, stromelysin-l (MMP-3) degrades proteoglycans, and the two Type IV collagenases of molecular weights 72 KD (MMP-2) and 92 KD (MMP-9) are capable of degrading Types IV, V, VII, and X collagens, gelatin, .
The enzymes of the MMP family also share other similarities, including a common mode of activation, a conserved amino acid sequence in the putative metal-bindingjactive site region, and inhi- considerably weaker in stromal fibroblasts and endothelial cells. Labeling for 72 KD and 92 KD Type IV collagenase mRNA was also found in benign fibroadenomas and for 92 KD Type IV collagenase in non-neoplastic ducts and acini.
The results indicate that stromal cells have a more important role in the synthesis and degradation of BMs in breast carcinomas than previously thought and that production of these enzymes is not restricted to malignancy. (]fiktocbem bition by specific proteinase inhibitors, known as tissue inhibitors of metalloproteinases (TIMPs) (7-9). Considerable evidence supports the notion that the balance between the levels of extracellular MMPs and TIMPs is the primary determinant of the rate of extracellular matrix (ECM) tumover.
The function of two matrix MMPs, the 72 KD and 92 KD Type IV collagenases, has been postulated to be of crucial importance in the process of invasion and metastasis (10, Il) . This is based on data obtained mainly from biochemial studies on cultured malignant cells (10) (11) (12) (13) . However, the production of Type IV collagenases is not solely a characteristic of malignant tissue, since secretion of 72 KD Type IV collagenase has been demonstrated in fibroblasts, endothelial cells, osteoblasts, and macrophages (3. [14] [15] [16] and 92 KD Type IV collagenase in polymorphonuclear leukocytes, macrophages, and epidermal keratinocytes (2, 17, 18) .
Intracytoplasmic immunoreactivity for 72 KD Type IV collagenase has been reported in colon and breast carcinoma cells, and it has been suggested that the enzyme is synthesized by these cells (19, 20) . In situ hybridization results in lung, ovarian, and skin carcinomas have shown, however, that 72 KD Type IV collagenase mRNA synthesis mainly occurs in stromal fibroblasts and endothelial cells (21) (22) (23) . In basaliomas and squamous cell carcinomas of the skin, 92 KD Type IV collagenase mRNA synthesis takes place mainly in carcinoma cells (23) .
S O N , HURSKAINEN, HOYH'IYA, OMAKINEN, AUTIO-HARMAINEN
Here we present results that further support the notion that the stromal cells of tumors are the major site of synthesis of 72 KD Type IV collagenase, a1 (IV) chain of Type IV collagen, and B1 chain of laminin "As.
Conversely, the 92 KD Type IV collagenase is mostly produced by the epithelial ells of both malignant and benign breast tumors.
Materials and Methods
Mat&.
The material included 20 breast carcinomas and two fibroadenomas collected from the fdes of the Department of Pathology, Oulu University Central Hospital. All material was fixed in 10% neutral formalin and embedded in paraffin. The diagnoses and grades of the tumors were based on light microscopic examination of hematoxylin-eosin-stained sections according to the criteria set by the World Health Organization (24) . The pertinent clinical and histopathological data of the cases are shown in 'Iible 1.
RNA Probes and ISH. Preparation of paraffin sections for the ISH was as described elsewhere (22, 25, 26) . A 906 BP PstI fragment from B1 chain cDNA clone HL 2 coding for the BII domain of the laminin (27) . a 916 BP BamH I-Hind 111 fragment from the cDNA clone HT 21 coding for the NC1 domain and part of the Yuntranslated region of the a1 (IV) collagen gene (28). and a 635 BP Scd-Sac1 fragment of the K-191 cDNA clone coding for the human 72 KD Type IV collagenase (29) were ligated into the M13 polylinker site of pSP64 and pSP65 vectors (Promega; Madison, WI). A 634 BP Xba I-Hind 111 fragment and a 574 BP Hind 111-Eco RI frag. ment of human 92 KD Type IV collagenase cDNA clone K-174.1 containing the 3' non-coding sequence (30) were subcloned into the pGEM 4 2 vector (Promega). For transcription ofthe riboprobes, a Riboprobe Gemini System Tianscription I1 kit (Promega) was used according to the manufacturer's insuuctions and the transcripts were labeled by ["S]-UTP for ISH. All solutions were treated with 0.1% diethylpyrocarbonate (DEPC) (Fluka.; Buchs, Switzerland). The pre-hybridization steps included incubation in 0.2 M HC1 for 20 min at room temperature (RT), followed by a 5-min wash in DEPC-H20 and treatment with proteinase K (1 mg/ml, 15-30 min. 37'C). The sections were then treated with 0.2% glycine in PBS, pH 7.2, for 30 sec and washed twice in PBS for 30 sec. Proteolysis was stopped by immersing the sections in 4% paraformaldehyde in PBS for 20 min. The sections were acetylated in 0.25-0.5% acetic anhydride in 0.1 M triethanolamine for 10 min, washed in PBS, and dehydrated. The sections were then allowed to air-dry for 1-2 hr at RT.
For hybridization, the sections were first incubated for 2 hr in the hybridization mixture without the probe, after which the radioactive hybridization mixture was placed on the sections. Before adding to the sections, the hybridization mixture was boiled for 1 min and then placed on ice to denature the probe. The hybridization mixture contained the radioactive RNA probe, 10 mM DIT, 10 mM Tris-HCI, 10 mM NaP04.5 mM EDTA, 0.3 M NaCI, yeast tRNA (1 mg/ml), deionized fonnamide 50% of the volume, and dextran sulfate 10% of the volume, 0.02% (w/v) Ficoll, 0.02% (w/v) polyvinylpyrrolidone, and bovine serum albumin (0.2 mglml). Approximately 3 x lo6 cpm/40 PI aliquot of hybridization mixture was placed on each section and the sections were covered with DEPC-HzOwashed coverslips. Hybridization was allowed to take place at 5O' C overnight. After hybridization, the coverslips were immersed at 60'C twice for 30 min in a washing buffer containing all the constituents of the hybridization mixture except for daruan sulfite and tRNA. Slides were then washed in fresh buffer at 50'C for 2 hr, rinsed in 0.5 M NaCl in 10 mM Tris-HCl, 1 mM E m (TE) at 37'C for 15 min, and then incubated in 0.5 M NaCl in TE containing 40 pg/ml RNAse A (Sigma; St Louis, MO) at 37'C for 30 min. Washings were as follows: 0.5 M NaCl in TE (37°C 15 min), 2
x SSC (45'C. twice for 15 min), 1 x SSC (45'C. twice for 15 min). After washings, the sections were dehydrated in a graded series of ethanol containing 300 mM ammonium acetate and air-dried at RT for 1-2 hr.
Autoradiography was performed by dipping the slides into Kodak NTB-3 nuclear track emulsion diluted 1:1 with 1% glycerol in H20. After exposure for 7-15 days, the slides were developed in Kodak D19 developer at RT for 5 min, rinsed in acetic acid, and fixed for 5 min at RT. The sections were counterstained with hematoxylin-eosin.
Labeling was assessed by counting the number of grains separately on the neoplastic cell, stromal fibroblast, and endothelial cell compartments. Only cells with >lo grains/cell were interpreted as unequivocally positive.
This was based on the observation that with the sense probes, used as a control in all cases, there was nonspecific labeling with 2-10 grainslcell. The signal level was assessed on a semiquantitative scale as follows: -, no positive cells (0%); c, occasional positive cells (<5%); + +, moderate amount of positive cells (5-50%); + + +, most or all the cells positive (>50%). Brightfield images were used to analyze the morphological details, whereas the intensity of iabeling was assessed from darkfield images.
Immunohistochemistry. To compare the ISH results of 72 KD and 92 KD Type IV collagenases with immunohistochemistry, two infiltrating ductal carcinomas, one mucinous carcinoma, one ductal carcinoma in situ, and two fibroadenomas were stained with monoclonal antibodies (MAb) to the 72 KD and 92 KD Type IV collagenases. For immunohistochemical staining, 4-pm-thidc @ i sections were stained by the avidin-biotinylated horseradish peroxidase (ABC) complex technique (Dako; Dakopatts AIS, Glosuup, Denmark). Before antigen-antibody reaction, the endogenous peroxidase was inactivated with 0.1% HzO2 in methanol. The primary antibody was used at a dilution of 1:25. For control stainings, PBS and normal rabbit serum were used instead of the primary antibody.
PlElT

Type IV collagen
FIEIT
Lminin
FIEIT
Infiltrative carcinomas
i i + i/i i / - i i i/i i i / - i i i / + / - i i i/i i i / - i i i / -/ - i i/i i / - i i/i/i -/ -/ - i/i -/ - i/i/- i i / -/ - i i i/i i i / - i i i/i/- i + i/i/- i i/i/- i i i/i i i / - i i i/i i + / - i i / + / - i / -/ - i i i/i/- i / -/ - -/ -/ -
In situ carcinomas
Production of the MAb to the human 72 KD Type IV collagenase has been described previously (26) , and the antibody is commercially available (cat no. CA-4001) from Molecular Oncology, Inc. (Gaithersburg, MD).
Production and Characterization of MAb Against the 92 KD Type IV Collagenase. MAb were produced by use of standard protocols (31). Briefly, 5-6-week-old female Balbk mice were immunized at +week intervals with 20 pg antigenlmouse emulsified in Freud's adjuvant (Difco; Detroit, MI). Serum samples were tested after the second booster and the mouse showing the best response against the antigen in direct ELSA was selected for fusion. Spleen cells from the immunized animal were fused with a mouse myeloma cell line (P3-X63-Ag8.653) using polyethylene glycol (Gibco PEG 4000) (Gibco; Grand Island, NY). Hybrid cells were selected on 96-well plates in HA-T medium [DMEM high glucose (Gibco) supplemented with 10% NCTC-135 (Gibco), 10% CPSR serum (Sigma), 10% fetal bovine serum (Sigma), 5% Origen HCF (Igen; Rockville, MD), HA-T supplement (Gibco 50X), and Penicillin/Streptomycin Solution (Gibco loox)].
Hybrid cells were screened by direct ELBA against the antigen and those positive were further screened by Western blot. Positive wells were cloned by the limiting dilution method and wells having single colonies were screened with direct ELISA. Medium from positive hybrids was collected and the MAb purified with protein G-Sepharose affinity chromatography (Pharmacia; Uppsala, Sweden). The isotype of the MAb was identified with a mouse hybridoma subisotyping kit (Calbiochem; La Jolla, CA).
Results
The ISH results are summarized in Eble 2.
Labeling with the 72 KD Type IV collagenase probe was seen in stromal fibroblasts in 19 malignant breast tumors and in one fibroadenoma. It was most intense in stromal fibroblasts of infiltrating duct carcinomas ( Figure I) , and there was a correlation between labeling density and the low differentiation degree of the tumors. In in situ carcinomas, the fibroblasts surrounding the neoplastic ducts also showed signal for the 72 KD Type IV collagenase "A.
Endothelial cells of stromal capillaries showed hybridization signals in 16 cases. Labeling of carcinoma cells with 72 KD Type IV collagenase probe was seen in only one case of infiltrating duct carcinoma. There was no correlation between the signal for 72 KD Type IV collagenase mRNA and tumor size or the presence of metastases.
The strongest labeling for 92 KD Type IV collagenase mRNA was found in neoplastic epithelial cells. The signal was weaker in stromal fibroblasts and endothelial cells. An equal level of labeling was seen in infiltrative and in situ carcinoma cells (Figure 2) . There was no correlation between the intensity of signal and tumor differentiation, tumor size, or the presence of metastases. In contrast to 72 KD Type IV collagenase, labeling for 92 KD Type IV . . , i-, +: <. Figure 1 . In an infiltrating duct carcinoma, strong signals for 72 KD Type IV collagenase can be Seen in stromal fibroblasts (arrows). In situ hybridi&ion. Original magnification x 260. Bar = 50 pm. collagenase mRNA was also found in non-neoplastic breast ducts adjacent to carcinoma areas (Figure 3) .
The most intense signal levels for the al(1V)chain of Type IV collagen mRNA were seen in stromal fibroblasts and in endothelial cells (Figure 4) . Labeling was seen in them in 14 and 10 carcinoma cells, respectively. It was highest in poorly differentiated infiltrating duct carcinomas. No labeling was present in neoplastic duct cells or in fibroadenomas.
Intense labeling for laminin mRNA was seen in stromal fibroblasts, and was strongest in poorly differentiated infiltrating duct carcinomas ( Figure 5 ). Somewhat weaker labeling was seen in endothelial cells. In five cases, the carcinoma cells also showed signal for laminin mRNA. All these cases were infiltrating carcinomas. No signal for laminin mRNA was seen in fibroadenomas.
Immunohistochemical Findings. All the tumors investigated showed strong intracytoplasmic staining with both 72 KD and 92 KD Type IV collagenase antibodies in the carcinoma cells (Figures  6 and 7) . The cytoplasm of fibroblasts and endothelial cells was also stained, and the staining intensity was stronger with the 72 KD Type IV collagenase antibodies (Figures 6 and 7) . The epithelial cells of normal ducts were stained with both antibodies, but the staining reaction was weaker compared with that in carcinoma cells.
Discussion
The results of this study show that the 72 KD Type IV collagenase, the a1 (IV) chain of Type IV collagen, and the laminin B1 chain mRNA are abundant in stromal fibroblasts and endothelial cells of breast carcinomas and virtually absent in the neoplastic and nonneoplastic epithelial cell compartment. These results are in line with recent findings showing that stromal cells are also the main site of 72 KD collagenase, Type IV collagen, and laminin mRNA synthesis in lung and ovarian carcinomas (21, 22) and in developing tissues (25) .
It is a commonly held view in cancer biology that production of BM-degrading enzymes by cancer cells is necessary for invasive growth (lOJ1). In line with this, immunohistochemical studies have shown intracytoplasmic immunoreactivity for 72 KD Type IV collagenase in breast and colon carcinoma cells (19, ZO) . In addition, in this study strong immunostaining for the 72 KD Type IV collagenase was observed in carcinoma cells. How can the present ISH data be reconciled with these seemingly discordant results? One mechanism could be that stromal cells in the secretion of 72 KD collagenase would use a constitutive pathway that indicates a continuous secretion of the protein without any storage, whereas carcinoma cells would use a regulatory pathway according to which the protein is stored in dense-core granules until release (32.33). If carcinoma cells would use mainly the regulatory pathway, this could explain the positive immunohistochemistry in carcinoma cells and account for their low synthetic rate of mRNA.
Another alternative is that carcinoma cells take up 72 KD Type IV collagenase on their surface, which would account for the immunohistochemical positivity. Such an attachment would require the presence of a receptor on the surface of the cells. In fact, Type IV collagen-degrading enzymes of nearly identical molecular weights to 72 KD and 92 KD enzymes have been isolated from cell membranes of some cultured carcinoma cells (34). Moreover, cell membrane-associated binding of exogenous 72 KD Type IV collagenase has recently been reported in breast carcinoma cell lines (35).
The labeling for 92 KD Type IV collagenase mRNA differed considerably from that for the 72 KD Type IV collagenase and was mainly seen in epithelial cells, irrespective of whether they were benign or malignant. In view ofthe postulated critical role of Type IV collagenase activity in tumor invasion, this suggests that 92 KD, but not 72 KD, Type IV collagenase would be an important phenotypical trait. This is not likely, however, since 92 KD Type IV collagenase is also present in non-neoplastic epithelium of normal breast ducts.
Rather, 92 KD Type IV collagenase synthesis is an inherent property of breast epithelial cells.
The collagenolytic BM-degrading capacity of tumor cells is not only dependent on the presence of collagenolytic enzymes but is also susceptible to regulation by several protease inhibitors. Proteases and their inhibitors form a highly balanced system in which lack of inhibitory activity could lead to heightened collagenolytic activity. An interesting concept has recently been published by Alexander and Werb (36), who showed that inactivation of the TIMP-1 gene leads to increased invasiveness of embryonic primitive mesenchymal cell lines and proposed that the capacity of tumor cells to invade neighboring tissue would depend on the balance of the synthesis of collagenolytic enzymes and their inhibitors (36). Indeed, it has been shown that transfection of melanoma cell lines with an expression vector to overproduce TIMP-1 leads to decreased invasiveness of the tumor cells (37). It appears that analysis of the distribution of mRNA expression for TIMP-1, TIMP-2, and interstitial collagenases would be of crucial importance to broaden our knowledge about the synthesis of regulatory proteins that are involved in the process of malignant growth.
